PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across cancers and blood disorders at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress that underscores the companys commitment to delivering transformational therapies for patients. Data from more than 140 company-sponsored studies, investigator-sponsored studies and collaborations evaluating compounds across 28 cancer types and blood disorders will be featured at the two meetings.<\/p>\n
We have made significant progress for patients with cancer and blood disorders by delivering clinically meaningful and differentiated treatment choices across modalities such as CAR T, immunotherapy and erythroid maturation, said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. Driven by our deep understanding of human biology and leading scientific research, the results being presented at ASCO and EHA will provide greater insight into the potential for improving long-term outcomes, and rationale for moving innovative interventions into earlier lines of treatment. Beyond our data, we are focused on improving care for all patients through our Health Equity Commitments, aimed at increasing diversity in clinical trials, addressing health disparities, and investing in training for racially and ethnically diverse clinical investigators.<\/p>\n
Key data being presented by Bristol Myers Squibb at ASCO and EHA 2022 include:<\/p>\n
Solid Tumor<\/p>\n
Cell Therapy<\/p>\n
Hematology<\/p>\n
Early Assets<\/p>\n
Summary of Presentations<\/p>\n
Select Bristol Myers Squibb studies at the 2022 ASCO Annual Meeting include:<\/p>\n
Abstract Title<\/p>\n
Author<\/p>\n
Presentation Type\/#<\/p>\n
Session Title<\/p>\n
Session Date\/ Time<\/p>\n
Acute Myeloid Leukemia<\/p>\n
Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R\/R AML).<\/p>\n
Courtney DiNardo<\/p>\n<\/p>\n
Poster<\/p>\n
Abstract #7032<\/p>\n<\/p>\n
Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant<\/p>\n
Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT<\/p>\n
Assessing eligibility for non-intensive chemotherapy (IC) randomized clinical trials (RCT) in patients (pts) with newly diagnosed (ND) AML from the Connect Myeloid Disease Registry.<\/p>\n
Harry Erba<\/p>\n
Poster<\/p>\n
Abstract #7029<\/p>\n
Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant<\/p>\n
Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT<\/p>\n
Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.<\/p>\n
Stephane De Botton<\/p>\n
Oral<\/p>\n
Abstract #7005<\/p>\n<\/p>\n
Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant<\/p>\n
Tuesday, June 7, 2022: 10:45 AM - 1:45 PM EDT<\/p>\n
Gastrointestinal<\/p>\n
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.<\/p>\n
Ian Chau<\/p>\n
Poster<\/p>\n
Abstract<\/p>\n
#4035<\/p>\n
Gastrointestinal CancerGastroesophageal, Pancreatic, and Hepatobiliary<\/p>\n
Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT<\/p>\n
Nivolumab (NIVO) ipilimumab (IPI) in patients (pts) with microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.<\/p>\n
Michael Overman<\/p>\n
Poster<\/p>\n
Abstract<\/p>\n
#3510<\/p>\n
Gastrointestinal CancerColorectal and Anal<\/p>\n
Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT<\/p>\n
Genitourinary<\/p>\n
Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.<\/p>\n
Cristina Suarez<\/p>\n<\/p>\n
Oral<\/p>\n
Abstract<\/p>\n
#4501<\/p>\n
Genitourinary CancerKidney and Bladder<\/p>\n<\/p>\n
Friday, June 3, 2022: 3:45 PM - 6:45 PM EDT<\/p>\n
The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.<\/p>\n
David Cella<\/p>\n
Oral<\/p>\n
Abstract<\/p>\n
#4502<\/p>\n
Genitourinary CancerKidney and Bladder<\/p>\n
Friday, June 3, 2022: 3:45 PM - 6:45 PM EDT<\/p>\n
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.<\/p>\n
Daniel Geynisman<\/p>\n
Poster<\/p>\n
Abstract<\/p>\n
#4548<\/p>\n
Genitourinary CancerKidney and Bladder<\/p>\n
Saturday, June 4, 2022: 2:15 PM - 5:15 PM EDT<\/p>\n
Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.<\/p>\n
Lucia Carril-Ajuria<\/p>\n<\/p>\n
Poster<\/p>\n
Abstract<\/p>\n
#4538<\/p>\n
Genitourinary CancerKidney and Bladder<\/p>\n<\/p>\n
Saturday, June 4, 2022: 2:15 PM - 5:15 PM EDT<\/p>\n
Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial.<\/p>\n
Alfred Witjes<\/p>\n
Poster<\/p>\n
Abstract<\/p>\n
#4585<\/p>\n
Genitourinary CancerKidney and Bladder<\/p>\n
Saturday, June 4, 2022: 2:15 PM - 5:15 PM EDT<\/p>\n
Melanoma<\/p>\n
Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.<\/p>\n
Hussein A. Tawbi<\/p>\n<\/p>\n
Oral<\/p>\n
Abstract<\/p>\n
#9505<\/p>\n
Melanoma\/Skin Cancers<\/p>\n
Sunday, June 5, 2022: 10:45 AM - 1:45 PM EDT<\/p>\n
<\/p>\n
View post: <\/p>\n
Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders - Business...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across cancers and blood disorders at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress that underscores the companys commitment to delivering transformational therapies for patients. Data from more than 140 company-sponsored studies, investigator-sponsored studies and collaborations evaluating compounds across 28 cancer types and blood disorders will be featured at the two meetings. We have made significant progress for patients with cancer and blood disorders by delivering clinically meaningful and differentiated treatment choices across modalities such as CAR T, immunotherapy and erythroid maturation, said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb Continue reading